Clobazam - Lundbeck

Drug Profile

Clobazam - Lundbeck

Alternative Names: Frisium; Onfi; Urbanol

Latest Information Update: 23 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator OVATION Pharmaceuticals
  • Developer Lundbeck Inc
  • Class Antiepileptic drugs; Anxiolytics; Benzodiazepines
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lennox-Gastaut syndrome
  • New Molecular Entity No

Highest Development Phases

  • Marketed Lennox-Gastaut syndrome
  • Phase III Dravet syndrome; Epilepsy

Most Recent Events

  • 03 May 2018 Lundbeck LLC terminates a phase III trial due to recruitment issues in Epilepsy in USA (PO) (NCT02134366)
  • 12 Oct 2015 No recent reports on development identified - Phase-III for Lennox-Gastaut syndrome (Adjunctive treatment, In children, In adults) in Australia, Belarus, Lithuania and India (PO)
  • 22 Mar 2015 Lundbeck initiates enrolment in a phase III trial in Dravet syndrome (Adjunctive treatment, In infants, In children, In adolescents) in USA (NCT02187809)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top